MACROGENICS INC (MGNX) Fundamental Analysis & Valuation

NASDAQ:MGNX • US5560991094

Current stock price

3.141 USD
-0.04 (-1.23%)
Last:

This MGNX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MGNX Profitability Analysis

1.1 Basic Checks

  • MGNX had negative earnings in the past year.
  • MGNX had a negative operating cash flow in the past year.
  • In the past 5 years MGNX always reported negative net income.
  • MGNX had a negative operating cash flow in each of the past 5 years.
MGNX Yearly Net Income VS EBIT VS OCF VS FCFMGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • MGNX has a Return On Assets of -29.05%. This is in the better half of the industry: MGNX outperforms 68.02% of its industry peers.
  • The Return On Equity of MGNX (-134.23%) is worse than 61.08% of its industry peers.
Industry RankSector Rank
ROA -29.05%
ROE -134.23%
ROIC N/A
ROA(3y)-19.23%
ROA(5y)-32.14%
ROE(3y)-65.96%
ROE(5y)-73.32%
ROIC(3y)N/A
ROIC(5y)N/A
MGNX Yearly ROA, ROE, ROICMGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Gross Margin of MGNX (75.91%) is better than 84.01% of its industry peers.
  • In the last couple of years the Gross Margin of MGNX has declined.
  • The Profit Margin and Operating Margin are not available for MGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.27%
GM growth 5YN/A
MGNX Yearly Profit, Operating, Gross MarginsMGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MGNX Health Analysis

2.1 Basic Checks

  • MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MGNX has more shares outstanding
  • The number of shares outstanding for MGNX has been increased compared to 5 years ago.
  • MGNX has a worse debt/assets ratio than last year.
MGNX Yearly Shares OutstandingMGNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
MGNX Yearly Total Debt VS Total AssetsMGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -5.71, we must say that MGNX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -5.71, MGNX is not doing good in the industry: 65.32% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 1.26 is on the high side and indicates that MGNX has dependencies on debt financing.
  • The Debt to Equity ratio of MGNX (1.26) is worse than 76.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z -5.71
ROIC/WACCN/A
WACC9.07%
MGNX Yearly LT Debt VS Equity VS FCFMGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 5.10 indicates that MGNX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.10, MGNX is in line with its industry, outperforming 56.07% of the companies in the same industry.
  • MGNX has a Quick Ratio of 4.92. This indicates that MGNX is financially healthy and has no problem in meeting its short term obligations.
  • MGNX's Quick ratio of 4.92 is in line compared to the rest of the industry. MGNX outperforms 56.07% of its industry peers.
Industry RankSector Rank
Current Ratio 5.1
Quick Ratio 4.92
MGNX Yearly Current Assets VS Current LiabilitesMGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MGNX Growth Analysis

3.1 Past

  • MGNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.26%.
  • MGNX shows a decrease in Revenue. In the last year, the revenue decreased by -0.31%.
  • The Revenue has been growing slightly by 7.34% on average over the past years.
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8%
Revenue 1Y (TTM)-0.31%
Revenue growth 3Y-0.53%
Revenue growth 5Y7.34%
Sales Q2Q%113.03%

3.2 Future

  • Based on estimates for the next years, MGNX will show a decrease in Earnings Per Share. The EPS will decrease by -0.57% on average per year.
  • MGNX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.20% yearly.
EPS Next Y-65.1%
EPS Next 2Y-25.08%
EPS Next 3Y-8.56%
EPS Next 5Y-0.57%
Revenue Next Year-50.75%
Revenue Next 2Y-24.37%
Revenue Next 3Y-3.21%
Revenue Next 5Y1.2%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MGNX Yearly Revenue VS EstimatesMGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
MGNX Yearly EPS VS EstimatesMGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. MGNX Valuation Analysis

4.1 Price/Earnings Ratio

  • MGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGNX Price Earnings VS Forward Price EarningsMGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGNX Per share dataMGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • MGNX's earnings are expected to decrease with -8.56% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.08%
EPS Next 3Y-8.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MGNX Dividend Analysis

5.1 Amount

  • MGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MGNX Fundamentals: All Metrics, Ratios and Statistics

MACROGENICS INC

NASDAQ:MGNX (3/27/2026, 9:42:04 AM)

3.141

-0.04 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-11
Inst Owners65.3%
Inst Owner Change-17.4%
Ins Owners1.19%
Ins Owner Change1.16%
Market Cap199.64M
Revenue(TTM)149.50M
Net Income(TTM)-74.62M
Analysts75.38
Price Target3.47 (10.47%)
Short Float %6.7%
Short Ratio3.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)88.12%
Min EPS beat(2)22.41%
Max EPS beat(2)153.84%
EPS beat(4)4
Avg EPS beat(4)50.71%
Min EPS beat(4)8.09%
Max EPS beat(4)153.84%
EPS beat(8)6
Avg EPS beat(8)60.81%
EPS beat(12)7
Avg EPS beat(12)19.44%
EPS beat(16)9
Avg EPS beat(16)21.4%
Revenue beat(2)2
Avg Revenue beat(2)232.15%
Min Revenue beat(2)78.5%
Max Revenue beat(2)385.79%
Revenue beat(4)4
Avg Revenue beat(4)189.3%
Min Revenue beat(4)78.5%
Max Revenue beat(4)385.79%
Revenue beat(8)5
Avg Revenue beat(8)83.51%
Revenue beat(12)5
Avg Revenue beat(12)32.75%
Revenue beat(16)8
Avg Revenue beat(16)29.47%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)11.86%
EPS NQ rev (3m)11.86%
EPS NY rev (1m)-4.37%
EPS NY rev (3m)-4.37%
Revenue NQ rev (1m)75.66%
Revenue NQ rev (3m)75.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.34
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 3.59
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.31
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS2.35
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.05%
ROE -134.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.91%
FCFM N/A
ROA(3y)-19.23%
ROA(5y)-32.14%
ROE(3y)-65.96%
ROE(5y)-73.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.27%
GM growth 5YN/A
F-Score3
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.69%
Cap/Sales 1.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.1
Quick Ratio 4.92
Altman-Z -5.71
F-Score3
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)31.38%
Cap/Depr(5y)35.94%
Cap/Sales(3y)2.25%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8%
EPS Next Y-65.1%
EPS Next 2Y-25.08%
EPS Next 3Y-8.56%
EPS Next 5Y-0.57%
Revenue 1Y (TTM)-0.31%
Revenue growth 3Y-0.53%
Revenue growth 5Y7.34%
Sales Q2Q%113.03%
Revenue Next Year-50.75%
Revenue Next 2Y-24.37%
Revenue Next 3Y-3.21%
Revenue Next 5Y1.2%
EBIT growth 1Y34.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.53%
OCF growth 3YN/A
OCF growth 5YN/A

MACROGENICS INC / MGNX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MACROGENICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to MGNX.


What is the valuation status of MACROGENICS INC (MGNX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MACROGENICS INC (MGNX). This can be considered as Overvalued.


What is the profitability of MGNX stock?

MACROGENICS INC (MGNX) has a profitability rating of 1 / 10.


How financially healthy is MACROGENICS INC?

The financial health rating of MACROGENICS INC (MGNX) is 2 / 10.


Can you provide the expected EPS growth for MGNX stock?

The Earnings per Share (EPS) of MACROGENICS INC (MGNX) is expected to decline by -65.1% in the next year.